New York, NY 5/9/08—Enzo Biochem has acquired BIOMOL International for $15 million in cash, $3 million in unregistered stock, and earn outs over two year. BIOMOL is a provider of more than 3,300 products for the areas of signal transduction, lipid research, apoptosis, neuroscience and drug discovery with a research focus in functional proteomics. Based in Plymouth Meeting, Pennsylvania, with two subsidiaries in the UK, and 50 employees, BIOMOL has annual revenues of nearly $11.5 million and annual growth of approximately 9%. “Their manufacturing capabilities should serve to enhance Enzo Life Sciences’ operating margins. Moreover, its UK subsidiaries, Affiniti Limited and Affiniti Research Products Limited, are accredited under the ISO9001:2000 international quality management standard, providing Enzo with the ability to supply raw materials under the most rigorous quality standards,” said Enzo President Barry Weiner. The acquisition is expected to be accretive to earnings, prior to purchase accounting adjustments.